RVINE, Calif.--(BUSINESS WIRE)--Meyer Pharmaceuticals LLC announced today that it has obtained a license for a new drug technology for the treatment of inflammatory conditions such as arthritis and skin disease. The drug is a patented oligonucleotide (a small segment of DNA) that specifically blocks NF-kB, a transcription factor that activates pro-inflammatory genes. The technology is licensed from AnGes MG, Inc., a pharmaceutical company located in Osaka, Japan, and is currently in Phase II testing for the treatment of atopic dermatitis.
